Catalent boosts plasmid DNA manufacturing at Rockville with addition of ABEC fermenters
The company's custom single run single-use fermenters supplied on fast-track schedule to support flexible manufacturing of plasmid DNA
Catalent Cell & Gene Therapy has boosted capacity at its plasmid production facility in Rockville, Maryland after installing two 50L custom single run (CSR) single-use fermenters supplied by biopharmaceutical manufacturing services provider, ABEC.
The custom-designed systems, which are now in operation, were delivered on an accelerated schedule to meet Catalent’s specific process requirements and address strong demand for gene therapy manufacturing.
Because Catalent wanted to expand its plasmid DNA manufacturing capabilities, ABEC designed the fermenters to provide maximum process flexibility for a variety of plasmid products and to integrate into existing space in the Rockville facility.
ABEC said its CSR fermentation technology delivers process performance comparable to that of stainless-steel systems, ensuring highly productive and scalable fermentation processes.
The company is also supplying CSR single-use disposable containers (DCs) from its two in-house ISO-7 cleanroom manufacturing facilities in Bethlehem, PA and Fermoy, County Cork, Ireland.
These facilities, as well as ABEC’s qualification of multiple single-use instrument and component suppliers, will help to ensure a robust supply chain and short DC lead times, ABEC said.
Catalent took over the lease of Rockville from vaccine firm Novavax in 2019, as part of an $18 million deal.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...